Merck & Co., Inc. has addressed the risks associated with its forward-looking statements in connection with the Jefferies 2026 Global Healthcare Conference in London.
The company, based in Rahway, N.J., USA, noted these disclosures fall within the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The company said that its projections are based on current management beliefs and expectations, which are subject to significant uncertainties.
According to the company, there are no guarantees that pipeline candidates will secure required regulatory approvals or achieve commercial success. Merck said that if underlying assumptions prove inaccurate or if specific risks materialize, actual results may differ materially from those described in its forward-looking statements.
The company identified several factors that could influence these results, including general industry conditions, competition, and global economic factors such as interest rate and currency exchange rate fluctuations.
Merck cited the potential impact of pharmaceutical industry regulation and healthcare legislation, both in the United States and internationally, alongside global trends toward healthcare cost containment. The company also listed its ability to accurately predict future market conditions as a factor influencing potential results.
Additional challenges highlighted by the company include the following:
- Technological advances and new patents attained by competitors.
- Challenges inherent in new product development, including obtaining regulatory approval.
- Manufacturing difficulties or delays.
- Financial instability of international economies and sovereign risk.
- Dependence on the effectiveness of company patents and other protections for innovative products.
- Exposure to litigation, including patent litigation, and regulatory actions.
Merck said that it undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information or future events. The company further advised that information provided remains current only as of the date presented, and investors should not rely upon the information as accurate after the presentation date.
Additional factors regarding these risks are detailed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings available on the Securities and Exchange Commission website.
